Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.0006
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 191842692000.0
- FreeCF/Share 6.7321
- PFCF 11.259
- PE 11.0915
- Debt/Assets 0.3027
- DivYield 0.0414
- ROE 0.3816
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.
Read More
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Merck Proves Why It's Still A Top Pharma Pick
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performance pleasantly surprised me in Q1 2025, and thanks to which Merck's operating income margin remains above 40%, are Vaxneuvance, Winrevair, and Welireg. From its oncology franchise, I highlight Welireg as a 'gem,' whose sales amounted to $137 million in the first three months of 2025, an increase of 61.2% year-on-year.
Read More
Merck Announces Third-Quarter 2025 Dividend
Published: May 27, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2025 Dividend.
Read More
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.
Read More
Should You Buy MRK Stock At $80?
Published: May 26, 2025 by: Forbes
Sentiment: Negative
Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.
Read More
Merck: Defensive Yield Meets Long-Term Optionality
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approval offering medium-term recovery potential.
Read More
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of the rare tumor TGCT, as well as data from both company- and investigator-sponsored studies highlighting the com.
Read More
Merck: Undervalued In Light Of Key Risks
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Negative
Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially Keytruda—drives strong segment performance, offsetting declines in virology and diabetes products. Management is aggressively investing in R&D and manufacturing expansion, with a robust drug pipeline and significant capital commitments to future growth.
Read More
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.
Read More
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
Read More
I'm Putting Cash To Work: 2 Rock-Solid Dividends At Bargain Prices
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm targeting value in overlooked sectors, highlighting Merck and Federal Realty as top picks for income and upside potential. Merck offers a low 8.5x PE, a 4.3% yield, a robust drug pipeline, and resilient growth despite Gardasil headwinds and tariff pressures. Federal Realty has premier assets, rising occupancy, low tenant risk, and a 4.5% yield, trading well below historical valuation multiples.
Read More
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Read More
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing research for patients with this disease. Merck will present pooled data from participants who have comple.
Read More
US FDA expands use of Merck's cancer drug for adrenal gland tumors
Published: May 14, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.
Read More
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Published: May 14, 2025 by: Barrons
Sentiment: Positive
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Surprise Breakthrough: US-China Talks Spark Market Rally
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
An unexpected thaw in US-China trade relations is sending US equity markets soaring this morning.
Read More
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal.
Read More
Merck Animal Health announces $895 million investment in Kansas
Published: May 08, 2025 by: Reuters
Sentiment: Positive
Merck Animal Health, a unit of Merck , said on Thursday it would invest $895 million to expand its manufacturing facility in De Soto, Kansas.
Read More
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895 million expansion of Merck Animal Health's manufacturing facility in De Soto, Kansas. The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It inc.
Read More
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bank of America 2025 Global Healthcare Conference.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should Investors Buy Merck Stock After These Huge Risks?
Published: April 30, 2025 by: The Motley Fool
Sentiment: Neutral
The performance of healthcare companies is relatively uncorrelated with broader macroeconomic growth.
Read More
3 Names I Picked Up In The Latest Market Slump
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting some of that cash to work. With April's market slump, putting cash to work is exactly what I was doing; today, we are looking at 3 of the names that I added to during this market decline.
Read More
Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda
Published: April 29, 2025 by: New York Post
Sentiment: Positive
The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.
Read More
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports
Published: April 29, 2025 by: Reuters
Sentiment: Positive
U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall Street Journal reported on Tuesday.
Read More
Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom
Published: April 29, 2025 by: WSJ
Sentiment: Positive
The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.
Read More
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert M. Davis J.D.
- Employees 73000